Navigation Links
Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use
Date:6/28/2013

Putnam Valley, NY. (June 28 2013) A study carried out in India examining the safety and efficacy of self-donated (autologous), transplanted bone marrow stem cells in patients with type 2 diabetes (TD2M), has found that patients receiving the transplants, when compared to a control group of TD2M patients who did not receive transplantation, required less insulin post-transplantation.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0920bhansali.

"There is growing interest in the scientific community for cellular therapies that use bone marrow-derived cells for the treatment of type 2 diabetes mellitus and its complications," said study corresponding author Anil Bhansali, PhD professor and head of the Endocrinology Department at the Post Graduate Institute of Medical Education in Chandrigarh, India. "But the potential of stem cell therapy for this disease is yet to be fully explored."

While there is growing interest in using stem cell transplantation to treat TD2M, few studies have examined the utility of bone marrow-derived stem cells. By experimenting with bone marrow-derived stem cells, the researchers sought to exploit the rich source of stem cells in bone marrow.

Their study aimed at evaluating the efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with T2DM and who also had good glycemic control. Good glycemic control emerged as an important factor in the transplantation group and in the non-transplanted control group.

Cell transplantation had a significant impact on the patients in this study as those administered cells demonstrated a significant reduction in insulin requirement. A significantly smaller reduction in the insulin requirement of the control group was also observed but a "repeated emphasis on life style modification" was believed to be a contributing factor in this effect.

According to Dr. Bhansali, the strength of their study included the inclusion of a homogenous patient population with T2DM which exhibited good glycemic control, and the presence of a similar control group that did not get cell transplants.

"The efficacy and safety of stem cell therapy needs to be established in a greater number of patients and with a longer duration follow-up," concluded Bhansali and his co-authors. "The data available so far from animal and human studies is encouraging, however, it has enormous limitations."

The researchers recommended determining which type of stem cells -hematopoietic, bone marrow or placenta-derived - might be best to treat T2DM. In addition, they said that post-transplantation patients needed close monitoring for the development of neoplasia as stem cells - whether multipotent or pluripotent - have the potential for malignant transformation.

They concluded that "autologous bone marrow-derived stem cell therapy in patients with T2DM results in significant decrease in insulin dose requirement."


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. National Institutes of Health to fund research probing proteins linked to cancer, diabetes
2. Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies
3. New data on islet autoantibodies in young children defines early type 1 diabetes development
4. Breakthrough research of essential molecule reveals important targets in diabetes and obesity
5. From autism to diabetes to Parkinsons disease
6. Nanotechnology could help fight diabetes
7. Discovery of new hormone opens doors to new type 2 diabetes treatments
8. Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes
9. Our internal clocks can become ticking time bombs for diabetes and obesity
10. BUSM study reveals therapeutic targets to alter inflammation, type 2 diabetes
11. Shiner Beers launches nationwide support of TGen diabetes studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... India , February 3, 2016 ... the new market research report "Automated Fingerprint Identification System ... Search, Latent Search), Application (Banking & Finance, Government, Healthcare, ... published by MarketsandMarkets, the market is expected to be ... CAGR of 21.0% between 2015 and 2020. The transformation ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
(Date:2/1/2016)... -- Today, the first day of American Heart Month, the ... first of its kind workplace health solution that leverages ... first application of Watson to ... Welltok will create a new offering that combines AHA,s ... on Welltok,s health optimization platform. The effort is intended ...
Breaking Biology News(10 mins):
(Date:2/6/2016)... McLean, VA (PRWEB) , ... February 06, 2016 , ... ... enrichment session, cost-free, for middle and high school teachers on Wednesday February 10, 2016. ... be held at the Smithsonian-Mason School of Conservation, located at 1500 Remount Road in ...
(Date:2/5/2016)... 2016  In the pharmaceutical industry the medical affairs ... launch activities including the identification and engagement of key ... especially high in the oncology therapeutic area where most ... the Role of Medical Affairs in Oncology Launch Excellence ... therapies find better ways to utilize medical affairs to ...
(Date:2/5/2016)... 2016 Australian-US drug discovery and development company, Novogen ... of a new Chairman, Mr John O,Connor , and ... James Garner , has also been formally ... Acting CEO, Mr Iain Ross , will resume his ... James Garner , has also been formally appointed to ...
(Date:2/4/2016)... Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today that Edward Lanphier , Sangamo,s president and ... progress of Sangamo,s ZFP Therapeutic ® development programs ... 2:40 pm ET on Thursday, February 11, 2016, at ... Conference. The conference is being held in ...
Breaking Biology Technology: